Share on StockTwits

Shire PLC (NASDAQ:SHPG) reached a new 52-week high during mid-day trading on Monday , StockRatingsNetwork reports. The company traded as high as $254.90 and last traded at $253.98, with a volume of 3,682,218 shares trading hands. The stock had previously closed at $249.06.

Several analysts have recently commented on the stock. Analysts at Zacks downgraded shares of Shire PLC from an “outperform” rating to a “neutral” rating in a research note on Friday, July 4th. They now have a $249.00 price target on the stock. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Shire PLC in a research note on Thursday, June 26th. They now have a $265.00 price target on the stock, up previously from $205.00. Finally, analysts at CRT Capital reiterated a “buy” rating on shares of Shire PLC in a research note on Monday, June 23rd. They now have a $250.00 price target on the stock, up previously from $195.00. Five analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $189.62.

The stock has a 50-day moving average of $203.7 and a 200-day moving average of $167.6. The company has a market cap of $49.626 billion and a P/E ratio of 57.53.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.36 EPS for the quarter, beating the Thomson Reuters consensus estimate of $2.22 by $0.14. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.38 billion. During the same quarter in the prior year, the company posted $0.35 earnings per share. The company’s quarterly revenue was up 17.8% on a year-over-year basis. On average, analysts predict that Shire PLC will post $9.79 earnings per share for the current fiscal year.

Shire plc (NASDAQ:SHPG) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.